|Videos|February 23, 2022
- Vol 50 No 06
- Volume 50
- Issue 06
Urology Times 50 Innovations Series: Clean intermittent catheterization
Author(s)Urology Times staff
"Intermittent catheterization is an important concept in urology, and it has a long history," says John Stoffel, MD.
Advertisement
In this installment of Urology Times®' 50th Anniversary Innovation Celebration series, John Stoffel, MD, discusses the development of clean intermittent catheterization and how it has improved the care of patients with urologic conditions. Stoffel is a Professor of Urology, and Chief of the Division Neurourology & Pelvic Reconstruction in the Department of Urology at the University of Michigan in Ann Arbor.
Articles in this issue
over 4 years ago
The role of mediation in medical malpractice litigationover 4 years ago
How do you bill for a 75-minute audio-only E/M visit?over 4 years ago
Telemedicine’s uncertain future in urologyover 4 years ago
Part D data reveal how urologists are prescribing antibioticsover 4 years ago
Same-side shock wave lithotripsy, URS present coding questionsover 4 years ago
What to consider when weighing pre-tax, Roth IRAsover 4 years ago
Dr. Amarasekera on supporting sexual minorities in healthcareAdvertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5